BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$1.61
+0.00 (+0.00%)
Open$1.61
Previous Close$1.61
Day High$1.61
Day Low$1.57
52W High$4.94
52W Low$1.60
Volume—
Avg Volume723.0K
Market Cap100.83M
P/E Ratio—
EPS$-0.74
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,131.1% upside
Current
$1.61
$1.61
Target
$35.92
$35.92
$30.62
$35.92 avg
$44.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 70.07M | 26.85M | 24.30M |
| Net Income | 22.39M | 2.09M | 2.49M |
| Profit Margin | 32.0% | 7.8% | 10.3% |
| EBITDA | 12.86M | 3.87M | 3.57M |
| Free Cash Flow | — | 2.98M | 2.09M |
| Rev Growth | — | +10.3% | +9.4% |
| Debt/Equity | — | 0.41 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |